Naoki Okumura

This inventor holds 18 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignees: The Doshisha, Kyoto Prefectural Public University Corporation, Senju Pharmaceutical Co., Ltd.. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Naoki Okumura. Retrieved from https://idiyas.com/inventor/naoki-okumura

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 6)

% Patents Active = 83.3

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 5 (Patent Applications = 5)

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Kyoto, JP (2014 - 2022)
Kyotanabe, JP (2017 - 2024)

Company Filing History:

Kyoto Prefectural Public University Corporation

patents

7 out of 229

Senju Pharmaceutical Co., Ltd.

Jcr Pharmaceuticals Co., Ltd.

patents

7. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12343356 - mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof (2025-07-01),

2. 11857544 - Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases (2024-01-02),

3. 11730722 - Corneal endothelium ECM therapeutic medicaments (2023-08-22),

4. 11633477 - Treatment of cornea using laminin (2023-04-25),

5. 11624053 - Application of laminin to corneal endothelial cell culture (2023-04-11),

6. 11576914 - Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof (2023-02-14),

7. 11446263 - Caspase inhibitor-containing drug for treating or preventing disorders caused by TGF-β, and applications thereof (2022-09-20),

8. 11445723 - Method and container for preserving corneal endothelial cells (2022-09-20),

9. 11433090 - mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof (2022-09-06),

10. 11382904 - Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium (2022-07-12),

11. 10980787 - Drug for treating or preventing disorder caused by TGF-B signals, and application thereof (2021-04-20),

12. 10959997 - Combined agent for cell therapy of corneal endothelial cell (2021-03-30),

13. 10908161 - Corneal endothelial cell marker (2021-02-02),

14. 10813920 - Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage (2020-10-27),

15. 10335439 - Method for producing human corneal epithelium sheet (2019-07-02),

Title: Naoki Okumura: Innovator in Ophthalmic Medicine

Introduction

Naoki Okumura, based in Kyoto, Japan, has made significant contributions to the field of ophthalmic medicine through his innovative research and inventions. With a total of 18 patents to his name, Okumura is a leading figure in the development of therapies aimed at treating corneal endothelial conditions. His work not only highlights the potential of mTOR inhibitors but also emphasizes the importance of addressing ophthalmic disorders.

Latest Patents

Okumura's latest patents focus on mTOR-inhibitor-containing medicines designed to treat or prevent various ophthalmic symptoms, disorders, or diseases. One notable invention is a composition specifically for preventing or treating corneal endothelial symptoms linked to the overexpression of the transforming growth factor-β (TGF-β) signal and extracellular matrix (ECM). This innovative approach represents a significant advancement in ophthalmic therapeutics. Another of his recent patents involves the use of (T)EW-7197, a derivative that provides a composition for treating or preventing symptoms of the corneal endothelium, opening new avenues for addressing debilitating eye conditions.

Career Highlights

Okumura's career is marked by his association with esteemed institutions such as Doshisha University and Kyoto Prefectural Public University Corporation, where he has excelled in research and development. His relentless pursuit of knowledge and innovation has positioned him as a leading inventor in the ophthalmic field.

Collaborations

Throughout his career, Naoki Okumura has had the opportunity to collaborate with distinguished colleagues, including Noriko Koizumi and Shigeru Kinoshita. These collaborations have not only enhanced his research capabilities but have also contributed to the advancement of ophthalmic science.

Conclusion

In conclusion, Naoki Okumura's groundbreaking work in ophthalmic medicine and his portfolio of 18 patents demonstrate his commitment to innovating solutions for complex eye disorders. His latest inventions underscore the potential of targeted therapies in improving patient outcomes and reflect the ongoing progress in the field of ophthalmology. As he continues to develop novel treatments, Okumura remains an influential figure in advancing medical science.

Profile summary based on public USPTO records.